The Future of Parenteral Nutrition: Innovations and Trends

September 4, 2025

Introduction: A Critical Examination of Parenteral Nutrition

Parenteral nutrition (PN) is an essential therapeutic approach for patients unable to meet their nutritional needs through oral or enteral routes. As medical practices and technologies advance, so too does our understanding and implementation of PN. This article explores the trajectory of parenteral nutrition, emphasizing innovations, challenges, and market trends that are shaping the future of patient care.

What is Parenteral Nutrition and Its Significance?

What is parenteral nutrition and why is it important?

Parenteral nutrition (PN) is defined as the intravenous administration of essential nutrients directly into the bloodstream. This method is particularly vital for patients who cannot obtain adequate nutrition through oral or enteral routes, often due to conditions like gastrointestinal disorders, surgical recovery, or critical illnesses.

Definition of parenteral nutrition

PN involves providing patients with macronutrients, including carbohydrates, proteins, and fats, alongside micronutrients such as vitamins, minerals, and trace elements. There are two primary types of parenteral nutrition:

  1. Total Parenteral Nutrition (TPN) : Delivers all necessary nutrients, generally for patients who are unable to eat or digest food.
  2. Peripheral Parenteral Nutrition (PPN) : Offers temporary supplementation, usually through a peripheral vein, and is often used for less complex cases.

Importance in medical treatment

PN is crucial for managing conditions related to intestinal failure, severe malabsorption, and prolonged inability to consume food orally. It helps maintain nutritional status, preserve muscle mass, and enhance recovery in critically ill patients. Additionally, with the increasing prevalence of chronic diseases, the role of PN is growing. For instance, around 34,000 patients in the United States receive PN annually, underscoring its importance in modern healthcare.

While lifesaving, parenteral nutrition is not without risks. Potential complications include infections, metabolic disturbances, and medication errors, which necessitate careful monitoring and management. A tailored approach by a healthcare team is essential to optimize outcomes and mitigate risks associated with PN administration.

Thus, parenteral nutrition is a fundamental component of patient care, ensuring necessary nutrients are provided when traditional feeding methods are inadequate, significantly improving the quality of life for those it serves.

Technological Innovations Transforming Parenteral Nutrition

How do advancements in technology impact parenteral nutrition?

Advancements in technology play a pivotal role in transforming parenteral nutrition, enhancing both formulation and delivery systems. A significant factor driving these changes is the rising prevalence of chronic diseases, such as cancer and gastrointestinal disorders, which often necessitate tailored nutritional support through parenteral methods.

Innovations in Formulation and Delivery Systems

New-generation lipid emulsions are a notable example of technological progress. For instance, the use of Fish Oil Lipid Emulsion (FOLE) has shown benefits in reducing PN-associated liver disease (PNALD), providing a safer option for patients. Similarly, the provision of premixed parenteral nutrition formulations allows for improved efficiency and safety by minimizing the risk of complications such as bloodstream infections, as they reduce preparation errors commonly associated with compounded solutions.

Benefits to Patient Care

These innovations are not just about technology; they translate into better patient care. Enhanced delivery systems, such as digital health tools for remote monitoring, now allow healthcare providers to manage nutritional assessments in real-time. This integration of technology enables patients to receive personalized nutritional support, which can improve recovery rates and overall health outcomes.

Advancements in parenteral nutrition highlight the importance of tailored nutrition solutions, particularly in home healthcare settings, where the rise of Home Parenteral Nutrition (HPN) enables patients to manage their nutritional needs independently. Overall, technological growth in this sector directly correlates with safer practices, better clinical outcomes, and significant projected market growth, expected to reach USD 12,456.8 million by 2034.

Dosing Guidelines for Safe Parenteral Nutrition Administration

What are the appropriate dosing recommendations for parenteral nutrition?

Appropriate dosing for parenteral nutrition (PN) should follow specific guidelines established by the American Society for Parenteral and Enteral Nutrition (ASPEN). It is essential for patients who cannot meet their nutritional needs through oral or enteral means, particularly those experiencing intestinal failure.

Initiation of Parenteral Nutrition

  • Critically ill patients should ideally start PN after day 6 of admission to the hospital.
  • For patients at risk of malnutrition, initiation within 3 to 6 days is recommended to mitigate the risk of further nutritional decline.

Nutritional composition and patient needs

The nutritional composition of PN must also be carefully considered. The protein needs for adult patients vary based on their condition. A recommended non-protein calorie to nitrogen ratio ranges from 70:1 to 100:1 for those who are critically ill. This balance ensures adequate protein while preventing excess caloric intake.

Fluid and electrolyte status are crucial components for safe PN administration. Close monitoring is essential to prevent complications like refeeding syndrome, which can occur with incorrect dosing. Additionally, trace elements should also be supplemented as per dosing guidelines based on individual patient weight, promoting tailored nutritional support.

Role of healthcare guidelines

The implementation of robust healthcare guidelines is critical in ensuring safe administration of PN. Healthcare providers must stay informed about the latest recommendations to adapt PN regimens to patient needs, thus optimizing outcomes and reducing risks associated with errors in dosage and composition.

Dosing Aspect Guideline Details
Initiation Timing Critically ill: after day 6; high risk: within 3-6 days Adjust based on condition
Protein Needs Non-protein calories/nitrogen ratio of 70:1 to 100:1 Ensures adequate protein intake
Monitoring Needs Fluid and electrolyte monitoring Prevent complications like refeeding syndrome
Trace Element Supplementation Based on patient weight Tailored to meet specific requirements

Proper adherence to these recommendations can significantly enhance the effectiveness of parenteral nutrition and improve patient outcomes.

Challenges in Clinical Practice and Safety Concerns

What challenges exist in the clinical practices of parenteral nutrition?

Clinical practices in parenteral nutrition (PN) encounter several serious challenges. One of the most critical is managing complications like infections, which can arise from the intravenous administration of nutrients. Additionally, the high risk of medication errors remains a significant concern, jeopardizing patient safety and complicating treatment efficacy.

The adequacy of nutrient mixes tailored for different patient populations is another challenge. Many healthcare professionals receive limited training on PN in medical programs, emphasizing the need for better education and training to ensure safe and effective treatment.

Moreover, global shortages of PN products can compromise therapy quality, particularly for patients relying on home parenteral nutrition (HPN). This scarcity heightens the risk of errors during prescription and administration, making it imperative to standardize formulations and adopt automated systems like Computerized Provider Order Entry and Electronic Health Records.

Education and training needs

To bridge the knowledge gap, continuous education initiatives targeted at healthcare workers can bolster safety in PN practices. Enhanced interdisciplinary communication should also be prioritized, ensuring that team members are well-informed about the complexities of PN therapies.

Standardization efforts

Standardizing nutrient formulations can minimize discrepancies in preparations, thus enhancing patient safety and care outcomes. Innovations in technology, such as automated systems for order entry and electronic health records, should be developed to streamline the PN process. By addressing these challenges, the clinical practice of parenteral nutrition can see significant improvements in both safety and efficacy.

Regulatory Frameworks and Their Role in Advancing Parenteral Nutrition

How do regulatory frameworks influence parenteral nutrition administration?

Regulatory frameworks play a crucial role in the administration of parenteral nutrition (PN) by setting safety standards that healthcare providers must follow. These standards ensure that patients receive high-quality, safe nutritional care tailored to their needs. By promoting the use of standardized compounding processes and multi-chamber bags (MCBs), regulatory guidelines help streamline the preparation and delivery of parenteral nutrition, enhancing not only patient safety but also cost-effectiveness.

Impact of regulatory standards

In hospitals, strict adherence to these regulatory frameworks can significantly improve PN systems. Hospitals are encouraged to share best practices and align their protocols with regulatory guidance. This collaborative approach is particularly beneficial for home parenteral nutrition (HPN), which necessitates thorough communication and education for both patients and their caregivers. Regulatory measures address the multifaceted nature of HPN, considering medical, psychosocial, and financial aspects to ensure comprehensive patient care.

Role of healthcare professionals and standardization

Healthcare professionals are vital to successful PN administration. Regulatory frameworks bolster their training and education, ensuring they are well-versed in PN protocols and best practices. Moreover, separating the complexities of peripheral parenteral nutrition (PPN) from traditional methods highlights the need for continuous learning in the field. Overall, regulatory standards drive awareness, push for standardized procedures, and foster a culture of safety, ultimately leading to better patient outcomes across various healthcare settings.

Aspect Details
Regulatory Frameworks Establish safety standards and promote standardization
Impact on HPN Improve patient education and streamline communication
Role of Healthcare Professionals Ensure compliance and enhance training in PN practices
Benefits of Standardization Increase patient safety and cost-effectiveness

Market Trends Influencing the Growth of Parenteral Nutrition

Market size and growth projections

The global parenteral nutrition market is expected to grow significantly, projecting a reach of USD 12,456.8 million by 2034 . This marks a substantial increase from USD 5,720.6 million in 2022 , with forecasts estimating revenues of USD 6,452.0 million by 2024 . This growth trajectory reflects a compound annual growth rate (CAGR) of 6.8% from 2024 to 2034 .

Factors driving demand

Several factors are propelling the demand for parenteral nutrition, including:

  • Rising prevalence of chronic diseases: With conditions such as cancer, diabetes, and gastrointestinal disorders becoming more common, the need for nutritional support via parenteral routes is critical.
  • Chronic illness among elderly populations: Aging populations are experiencing higher rates of malnutrition and metabolic disorders, driving the necessity for parenteral nutrition solutions.
  • Innovations in product formulation and delivery: Advances in nutritional formulations, such as the integration of new lipid emulsions and premixed solutions, enhance patient safety and outcomes.

Role of chronic diseases

Chronic diseases are a core component influencing market expansion. As these conditions often inhibit patients' ability to absorb nutrients orally, parenteral nutrition provides essential nutrients directly into the bloodstream, fulfilling a vital healthcare role. This trend is particularly pronounced among geriatric patients who face unique nutritional challenges due to their health status.

Innovations in Lipid Formulations and Delivery Systems

What are alternative lipid sources?

Traditional soybean oil lipid emulsions (SOLE) have been the cornerstone of parenteral nutrition for decades. However, SOLE has been linked to parenteral nutrition-associated liver disease (PNALD), highlighting the need for alternative lipid sources. Fish oil lipid emulsions (FOLE) have emerged as a promising option, showcasing improved outcomes in resolving PNALD. Moreover, new-generation lipid emulsions like SMOF—combining soy, medium-chain triglycerides, olive oil, and fish oil—are being explored for their potential in enhancing nutritional benefits while minimizing risks.

What benefits do new formulations offer?

The enhancement of PN formulations is pivotal for both hospital and homecare settings. Innovations such as multichamber bags allow for easier administration and potentially lower the risk of complications, like bloodstream infections, compared to traditional compounded solutions. Additional advancements, such as the ExactaMix Pro Automated Compounder, bolster patient safety and formulation accuracy, thus improving the overall efficiency of parenteral nutrition delivery.

How do these developments reduce PN-associated risks?

The move towards personalized nutrition through advanced lipid formulations is crucial. By including essential fats and micronutrients, these innovative products address specific patient needs while diminishing the risk of malnutrition. As the sector leans towards safety and efficacy, the combination of sophisticated infusion technologies and refined lipid formulations not only paves the way for better patient outcomes but also enhances the potential for home-based parenteral nutrition.

Personalization in Nutritional Care: A New Era for Parenteral Nutrition

Customized Nutritional Solutions

The growing demand for customized nutritional solutions is a game changer in the parenteral nutrition market. With advances in formulation technologies, healthcare providers can now create tailored nutrition plans that meet individual patients' specific dietary requirements. This trend is particularly important for populations such as premature infants and elderly patients who often face unique nutritional challenges.

Advancements in Patient-Specific Care

New-generation lipid emulsions and standardized total parenteral nutrition (TPN) formulations are leading the way in patient-specific care. These innovations not only address individual nutrient needs but also reduce the risk of complications associated with traditional methods. For instance, specialized amino acid mixtures cater to diverse patient profiles, ensuring that both essential and nonessential nutrients are delivered in optimal proportions.

Role of Personalized Medicine

The integration of personalized medicine into parenteral nutrition is also notable. Research shows that tailored supplementation of micronutrients can enhance patient outcomes significantly. By focusing on individual nutritional needs, healthcare providers can improve recovery rates and quality of life for those relying on parenteral nutrition, marking a significant shift towards precision in dietary management.

Importance of Interdisciplinary Care in Parenteral Nutrition

Role of healthcare teams

Successful parenteral nutrition (PN) requires collaboration among multidisciplinary healthcare teams. This includes physicians, pharmacists, dietitians, and nurses who work together to tailor nutritional solutions to each patient’s needs. The presence of trained pharmacists, in particular, is critical for managing complex HPN therapies and ensuring adherence to nutritional guidelines.

Coordination for optimal outcomes

Effective communication among team members enhances patient management and reduces the risk of medication errors. Establishing collaborative practice agreements allows pharmacists to take an active role in patient care, streamlining processes and improving adherence to nutrition protocols.

Impact on patient safety

Interdisciplinary care in PN also focuses on safety. Enhanced coordination minimizes the potential for complications such as bloodstream infections and nutrient imbalances. As technological advancements improve PN delivery, the team’s oversight becomes increasingly important to maintain safe and effective treatments.

Future Prospects and Research Directions in Parenteral Nutrition

Emerging Research Themes

The landscape of parenteral nutrition (PN) is evolving, with several vital research themes emerging. One significant area of focus is exploring immunonutrition, emphasizing the role of micronutrients like selenium and vitamins in enhancing patient recovery. Another research direction is the optimization of amino acid formulations tailored to specific patient needs, particularly in vulnerable populations such as neonates.

Impact on Global Health

As chronic diseases continue to rise, the implications for global health are profound. The increasing elderly population and rising rates of malnutrition underscore the pressing need for effective nutritional interventions. Parenteral nutrition plays a critical role in mitigating these issues by providing essential nutrients directly to patients unable to consume food orally, thereby addressing a significant healthcare gap.

Innovations on the Horizon

Several exciting innovations are set to redefine the future of parenteral nutrition. The development of automated compounding systems, such as Baxter's ExactaMix Pro, aims to enhance accuracy and efficiency in PN preparation. Furthermore, advancements in lipid formulations, such as new-generation emulsions that combine various fats, show promise in improving nutritional outcomes while minimizing complications associated with traditional emulsions.

These emerging areas of research and technological advancements position parenteral nutrition as a vital component of tailored patient care, paving the way for improved treatment approaches and enhanced patient safety in the coming years.

Conclusion: Shaping the Future of Parenteral Nutrition

As we continue to explore the evolving landscape of parenteral nutrition, it is evident that innovations in technology, personalized care, and regulatory adaptations will play crucial roles in the future of patient management. By addressing current challenges and leveraging advancements, the healthcare industry can improve patient outcomes and redefine nutritional support strategies. Through interdisciplinary collaboration and continuous research, the field of parenteral nutrition promises a healthier future for patients worldwide.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More